Table 5.
Influence of relaxin (or vehicle) administration by subcutaneous osmotic pump on cancellous and cortical morphometry of the femur
| BV/TV (%) | Tb.Th (mm) | Tb.N (#/mm) | Tb.Sp (mm) | Tb.Pf (#/mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| V | R | V | R | V | R | V | R | V | R | |
| Cancellous morphometry | ||||||||||
| Protocol 1 | 1.81 ± 0.19 | 2.74 ± 0.38 | 0.037 ± 0.001 | 0.044 ± 0.002 | 0.494 ± 0.049 | 0.626 ± 0.075 | 0.377 ± 0.030 | 0.379 ± 0.025 | 51.1 ± 0.65 | 42.8 ± 2.69 |
| P‐value | 0.094 | 0.030 | 0.229 | 0.957 | 0.040 | |||||
| 3D Ct.Th (mm) | Tt.Ar (mm2) | Ct.Ar (mm2) | Ma.Ar (mm2) | Ct.Ar/Tt.Ar (%) | ||||||
| V | R | V | R | V | R | V | R | V | R | |
| Cortical morphometry | ||||||||||
| Protocol 1 | 0.194 ± 0.004 | 0.193 ± 0.002 | 1.554 ± 0.026 | 1.616 ± 0.048 | 0.705 ± 0.011 | 0.719 ± 0.010 | 0.849 ± 0.025 | 0.897 ± 0.041 | 0.454 ± 0.008 | 0.446 ± 0.009 |
| P‐value | 0.897 | 0.313 | 0.360 | 0.363 | 0.560 | |||||
Mean ± SEM. V, vehicle; R, recombinant human relaxin.
Protocol 1: mice were euthanized ~11 weeks after implementing bilateral 1.5 mm cranial lesions and subcutaneous implantation of 14 day osmotic pumps containing recombinant human relaxin (rhRLX; 1.0 μg/h) or vehicle (n = 6 mice for relaxin and n = 4 mice for vehicle treatments). BV/TV, bone volume fraction; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Pf, trabecular pattern factor; Ct.Th, cortical thickness; Tt.Ar, total area inside the periosteal envelope; Ct.Ar, cortical bone area; Ma.Ar, medullary area; Ct.Ar/Tt.Ar, cortical bone area fraction.